-
Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions
•
Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with Shanghai-based Tower & Winner Solutions (TWS) to expand its operations into the Chinese market. The collaboration will make Tower Cold Chain’s temperature-controlled passive containers accessible to local pharmaceutical manufacturers, airlines, and third-party logistics companies for…
-
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option agreement with US firm Neurocrine Biosciences Inc. The agreement grants Neurocrine access to Biocytogen’s fully human antibodies targeting multiple specified therapeutic areas, with an option to license selected antibodies for global development, manufacturing, and commercialization.…
-
China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing Purevalley Biotechnology Co., Ltd and Chengdu Purevalley Biotechnology Co., Ltd, have entered into a distribution agreement with Australian firm Sirtex Medical Ltd. This agreement centers on the distribution of Sirtex’s SIR-Spheres (Y-90 microsphere) injection, a…
-
Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market
•
Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and Rayvow (lasmiditan) from U.S. partner Eli Lilly (NYSE: LLY) for the European market. Under the agreement, Lilly will receive an upfront payment of $50 million, along with milestone payments, pending regulatory approval expected in Q1…
-
European Commission Expands Keytruda Indications for Advanced Cancer Treatments
•
The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications for its leading anti-PD-1 therapy, Keytruda (pembrolizumab), approving its use as a first-line treatment in combination with chemotherapy for locally advanced unresectable or metastatic biliary tract carcinoma (BTC) and HER2-negative gastric or gastroesophageal junction (GEJ)…
-
HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD
•
HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for its CRISPR-Cas12 DNA editing therapy, HG302. This designation highlights the therapy’s potential to treat Duchenne muscular dystrophy (DMD), a severe neuromuscular genetic disorder. HG302 employs high fidelity Cas12 (hfCas12Max)…
-
Blue Sail Medical Partners with Weifang Government on Healthcare Initiative
•
China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the local government of Weifang, Shandong province, as well as Linqu county, also within Weifang. Under this partnership, the Weifang government plans to invest in Blue Sail, facilitating the introduction of various medical and healthcare-related projects…
-
HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors
•
Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the initiation of dosing for the first patient in a clinical trial of its candidate HFK1. This investigational drug is an immunoliposome encapsulating doxorubicin, aimed at targeting various solid tumors. The trial is being conducted concurrently…
